ACTIV-6
ACTIV-6, officially ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications, is an American study of repurposed drugs to treat COVID-19. The four drugs included in the study are ivermectin, fluvoxamine, fluticasone and montelukast.
It is part of the larger Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.
The study officially began on June 8, 2021, and is scheduled for completion in March 2024.1)
History
The study was first posted to ClinicalTrials.gov on May 13, 2021.2)
Participants
ACTIV-6 is being led by principal investigators Susanna Naggie and Adrian Hernandez at the Duke Clinical Research Institute.
Locations
Participating clinical trial sites include:
Funding
ACTIV-6 is funded by:3)